首页> 外文期刊>Antimicrobial agents and chemotherapy. >Effects of Klebsiella pneumoniae Carbapenemase Subtypes, Extended-Spectrum beta-Lactamases, and Porin Mutations on the In Vitro Activity of Ceftazidime-Avibactam against Carbapenem-Resistant K. pneumoniae
【24h】

Effects of Klebsiella pneumoniae Carbapenemase Subtypes, Extended-Spectrum beta-Lactamases, and Porin Mutations on the In Vitro Activity of Ceftazidime-Avibactam against Carbapenem-Resistant K. pneumoniae

机译:肺炎克雷伯菌肺炎克雷伯菌酶亚型,广谱β-内酰胺酶和孔蛋白突变对头孢他啶-阿维巴坦体外抗碳青霉菌耐药肺炎克雷伯菌的影响

获取原文
获取原文并翻译 | 示例
           

摘要

Avibactam is a novel beta-lactamase inhibitor with affinity for Klebsiella pneumoniae carbapenemases (KPCs). In combination with ceftazidime, the agent demonstrates activity against KPC-producing K. pneumoniae (KPC-Kp). KPC-Kp strains are genetically diverse and harbor multiple resistance determinants, including defects in outer membrane proteins and extended-spectrum beta-lactamases (ESBLs). Mutations in porin gene ompK36 confer high-level carbapenem resistance to KPC-Kp strains. Whether specific mechanisms of antimicrobial resistance also influence the activity of ceftazidime-avibactam is unknown. We defined the effects of ceftazidime-avibactam against 72 KPC-Kp strains with diverse mechanisms of resistance, including various combinations of KPC subtypes and ESBL and ompK36 mutations. Ceftazidime MICs ranged from 64 to 4,096 mu g/ml and were lowered by a median of 512-fold with the addition of avibactam. All strains exhibited ceftazidime-avibactam MICs at or below the CLSI breakpoint for ceftazidime (<= 4 mu g/ml; range, 0.25 to 4). However, the MICs were within two 2-fold dilutions of the CLSI breakpoint against 24% of the strains, and those strains would be classified as nonsusceptible to ceftazidime by EUCAST criteria (MIC > 1 mu g/ml). Median ceftazidime-avibactam MICs were higher against KPC-3 than KPC-2 variants (P = 0.02). Among KPC-2-Kp strains, the presence of both ESBL and porin mutations was associated with higher drug MICs compared to those seen with either factor alone (P = 0.003 and P = 0.02, respectively). In conclusion, ceftazidime-avibactam displays activity against genetically diverse KPC-Kp strains. Strains with higher-level drug MICs provide a reason for caution. Judicious use of ceftazidime-avibactam alone or in combination with other agents will be important to prevent the emergence of resistance.
机译:阿维巴坦是一种新型的β-内酰胺酶抑制剂,对肺炎克雷伯菌肺炎克雷伯菌(KPCs)具有亲和力。与头孢他啶组合使用时,该药物对产生KPC的肺炎克雷伯菌(KPC-Kp)具有活性。 KPC-Kp菌株在遗传上是多样的,并且具有多个抗性决定簇,包括外膜蛋白和广谱β-内酰胺酶(ESBLs)的缺陷。孔蛋白基因ompK36中的突变赋予KPC-Kp菌株高水平的碳青霉烯抗性。抗菌素耐药性的具体机制是否也会影响头孢他啶-avibactam的活性尚不清楚。我们定义了头孢他啶-avibactam对具有多种耐药机制的72种KPC-Kp菌株的作用,包括KPC亚型和ESBL和ompK36突变的各种组合。头孢他啶的MIC范围为64至4,096μg / ml,加入阿维巴坦后其中位数降低了512倍。所有菌株均显示出头孢他啶-avibactam MICs等于或低于头孢他啶的CLSI断裂点(<= 4μg / ml;范围为0.25至4)。但是,MIC在24%的菌株的CLSI断裂点的2倍稀释度之内,并且根据EUCAST标准(MIC> 1μg / ml),这些菌株将被归类为对头孢他啶不敏感。抗KPC-3的头孢他啶-avibactam MIC的中间值高于KPC-2变体(P = 0.02)。在KPC-2-Kp菌株中,ESBL和孔蛋白突变的存在与较高的药物MIC相比,与单独使用任一因子时所见的MIC更高(分别为P = 0.003和P = 0.02)。总之,头孢他啶-avibactam具有抗遗传多样性KPC-Kp菌株的活性。具有较高药物MIC的菌株提供了谨慎的理由。明智地单独使用头孢他啶-avibactam或与其他药物联合使用对预防耐药性的出现很重要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号